Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
dc.contributor.author | Lin, Nancy U. | en_US |
dc.contributor.author | Vanderplas, Ann | en_US |
dc.contributor.author | Hughes, Melissa E. | en_US |
dc.contributor.author | Theriault, Richard L. | en_US |
dc.contributor.author | Edge, Stephen B. | en_US |
dc.contributor.author | Wong, Yu‐ning | en_US |
dc.contributor.author | Blayney, Douglas W. | en_US |
dc.contributor.author | Niland, Joyce C. | en_US |
dc.contributor.author | Winer, Eric P. | en_US |
dc.contributor.author | Weeks, Jane C. | en_US |
dc.date.accessioned | 2012-11-07T17:04:43Z | |
dc.date.available | 2014-01-07T14:51:08Z | en_US |
dc.date.issued | 2012-11-15 | en_US |
dc.identifier.citation | Lin, Nancy U.; Vanderplas, Ann; Hughes, Melissa E.; Theriault, Richard L.; Edge, Stephen B.; Wong, Yu‐ning ; Blayney, Douglas W.; Niland, Joyce C.; Winer, Eric P.; Weeks, Jane C. (2012). "Clinicopathologic features, patterns of recurrence, and survival among women with tripleâ negative breast cancer in the National Comprehensive Cancer Network ." Cancer 118(22): 5463-5472. <http://hdl.handle.net/2027.42/94292> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/94292 | |
dc.description.abstract | BACKGROUND: The objective of this study was to describe clinicopathologic features, patterns of recurrence, and survival according to breast cancer subtype with a focus on triple‐negative tumors. METHODS: In total, 15,204 women were evaluated who presented to National Comprehensive Cancer Network centers with stage I through III breast cancer between January 2000 and December 2006. Tumors were classified as positive for estrogen receptor (ER) and/or progesterone receptor (PR) (hormone receptor [HR]‐positive) and negative for human epidermal growth factor receptor 2 (HER2); positive for HER2 and any ER or PR status (HER2‐positive); or negative for ER, PR, and HER2 (triple‐negative). RESULTS: Subtype distribution was triple‐negative in 17% of women (n = 2569), HER2‐positive in 17% of women (n = 2602), and HR‐positive/HER2‐negative in 66% of women (n = 10,033). The triple‐negative subtype was more frequent in African Americans compared with Caucasians (adjusted odds ratio, 1.98; P < .0001). Premenopausal women, but not postmenopausal women, with high body mass index had an increased likelihood of having the triple‐negative subtype ( P = .02). Women with triple‐negative cancers were less likely to present on the basis of an abnormal screening mammogram (29% vs 48%; P < .0001) and were more likely to present with higher tumor classification, but they were less likely to have lymph node involvement. Relative to HR‐positive/HER2‐negative tumors, triple‐negative tumors were associated with a greater risk of brain or lung metastases; and women with triple‐negative tumors had worse breast cancer‐specific and overall survival, even after adjusting for age, disease stage, race, tumor grade, and receipt of adjuvant chemotherapy (overall survival: adjusted hazard ratio, 2.72; 95% confidence interval, 2.39‐3.10; P < .0001). The difference in the risk of death by subtype was most dramatic within the first 2 years after diagnosis (overall survival for 0‐2 years: OR, 6.10; 95% confidence interval, 4.81‐7.74). CONCLUSIONS: Triple‐negative tumors were associated with unique risk factors and worse outcomes compared with HR‐positive/HER2‐negative tumors. Cancer 2012. © 2012 American Cancer Society. The authors evaluate 15,204 women who presented to National Comprehensive Cancer Network centers with stage I, II, and III breast cancer between January 2000 and December 2006. The results indicate that, relative to patients with hormone receptor‐positive/HER2‐negative breast cancer, patients with triple‐negative tumors have unique presenting features and clinical risk factors, and they experience significantly worse outcomes, even after controlling for age, stage, race, grade, and receipt of adjuvant chemotherapy. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Obesity | en_US |
dc.subject.other | Triple‐Negative | en_US |
dc.subject.other | Basal‐Like | en_US |
dc.subject.other | Breast Cancer | en_US |
dc.subject.other | Outcomes | en_US |
dc.subject.other | Brain Metastases | en_US |
dc.subject.other | Race | en_US |
dc.title | Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Dana‐Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, Stanford University Cancer Center, Palo Alto, California | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Division of Information Sciences, City of Hope Comprehensive Cancer Center, Duarte, California | en_US |
dc.contributor.affiliationother | Department of Population Sciences, Dana‐Farber Cancer Institute, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Breast and Soft Tissue Surgery, Roswell Park Cancer Institute, Buffalo, New York | en_US |
dc.identifier.pmid | 22544643 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/94292/1/27581_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.27581 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple‐negative breast cancer. Breast Cancer Res Treat. 2010; 121: 479 ‐ 483. | en_US |
dc.identifier.citedreference | Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in 2 prospective cohort studies of breast cancer survivors [serial online]. Breast Cancer Res. 2009; 11: R31. | en_US |
dc.identifier.citedreference | Lara‐Medina F, Perez‐Sanchez V, Saavedra‐Perez D, et al. Triple‐negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011; 117: 3658 ‐ 3669. | en_US |
dc.identifier.citedreference | Vona‐Davis L, Rose DP, Hazard H, et al. Triple‐negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3319 ‐ 3324. | en_US |
dc.identifier.citedreference | Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28: 3271 ‐ 3277. | en_US |
dc.identifier.citedreference | Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747 ‐ 752. | en_US |
dc.identifier.citedreference | Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple‐negative/basal‐like breast carcinomas [serial online]. Breast Cancer Res. 2007; 9: R65. | en_US |
dc.identifier.citedreference | Schneider BP, Winer EP, Foulkes WD, et al. Triple‐negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008; 14: 8010 ‐ 8018. | en_US |
dc.identifier.citedreference | Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492 ‐ 2502. | en_US |
dc.identifier.citedreference | Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population‐based study. Cancer Epidemiol Biomarkers Prev. 2007; 16: 439 ‐ 443. | en_US |
dc.identifier.citedreference | Dent R, Trudeau M, Pritchard KI, et al. Triple‐negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13 ( 15 pt 1 ): 4429 ‐ 4434. | en_US |
dc.identifier.citedreference | Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype: a population‐based study from the California Cancer Registry. Cancer. 2007; 109: 1721 ‐ 1728. | en_US |
dc.identifier.citedreference | Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2‐overexpressing, and triple‐negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2078 ‐ 2086. | en_US |
dc.identifier.citedreference | Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal‐like breast cancer. Breast Cancer Res Treat. 2008; 109: 123 ‐ 139. | en_US |
dc.identifier.citedreference | Stead LA, Lash TL, Sobieraj JE, et al. Triple‐negative breast cancers are increased in black women regardless of age or body mass index [serial online]. Breast Cancer Res. 2009; 11: R18. | en_US |
dc.identifier.citedreference | Troester MA, Swift‐Scanlan T. Challenges in studying the etiology of breast cancer subtypes [serial online]. Breast Cancer Res. 2009; 11: 104. | en_US |
dc.identifier.citedreference | Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113: 2638 ‐ 2645. | en_US |
dc.identifier.citedreference | Punglia RS, Hughes ME, Edge SB, et al. Factors associated with guideline‐concordant use of radiotherapy after mastectomy in the National Comprehensive Cancer Network. Int J Radiat Oncol Biol Phys. 2008; 72: 1434 ‐ 1440. | en_US |
dc.identifier.citedreference | Dawood S, Broglio K, Kau SW, et al. Triple receptor‐negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009; 27: 220 ‐ 226. | en_US |
dc.identifier.citedreference | Berry DA, Cirrincione C, Henderson IC, et al. Estrogen‐receptor status and outcomes of modern chemotherapy for patients with node‐positive breast cancer. JAMA. 2006; 295: 1658 ‐ 1667. | en_US |
dc.identifier.citedreference | Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node‐positive breast cancer. N Engl J Med. 2007; 357: 1496 ‐ 1506. | en_US |
dc.identifier.citedreference | Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early stage breast cancer. N Engl J Med. 2009; 360: 2055 ‐ 2065. | en_US |
dc.identifier.citedreference | Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple‐negative breast cancer, including race. Cancer Causes Control. 2009; 20: 1071 ‐ 1082. | en_US |
dc.identifier.citedreference | Manders P, Pijpe A, Hooning MJ, et al. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2012; 126: 193 ‐ 202. | en_US |
dc.identifier.citedreference | Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin‐like growth factor‐I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009; 101: 48 ‐ 60. | en_US |
dc.identifier.citedreference | Vatten LJ, Holly JM, Gunnell D, Tretli S. Nested case‐control study of the association of circulating levels of serum insulin‐like growth factor I and insulin‐like growth factor binding protein 3 with breast cancer in young women in Norway. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2097 ‐ 2100. | en_US |
dc.identifier.citedreference | Harris LN, Broadwater G, Lin NU, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 [serial online]. Breast Cancer Res. 2006; 8: R66. | en_US |
dc.identifier.citedreference | Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol). 2008; 20: 40 ‐ 45. | en_US |
dc.identifier.citedreference | Fulford LG, Reis‐Filho JS, Ryder K, et al. Basal‐like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long‐term survival [serial online]. Breast Cancer Res. 2007; 9: R4. | en_US |
dc.identifier.citedreference | Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007; 13: 1648 ‐ 1655. | en_US |
dc.identifier.citedreference | Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006; 17: 935 ‐ 944. | en_US |
dc.identifier.citedreference | Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER‐2 status. Cancer. 2008; 112: 2359 ‐ 2367. | en_US |
dc.identifier.citedreference | Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor‐negative breast cancer and brain metastases. Ann Oncol. 2009; 20: 621 ‐ 627. | en_US |
dc.identifier.citedreference | Bertucci F, Finetti P, Cervera N, et al. How basal are triple‐negative breast cancers? Int J Cancer. 2008; 123: 236 ‐ 240. | en_US |
dc.identifier.citedreference | Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal‐like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367 ‐ 5374. | en_US |
dc.identifier.citedreference | Cheang MC, Voduc D, Bajdik C, et al. Basal‐like breast cancer defined by 5 biomarkers has superior prognostic value than triple‐negative phenotype. Clin Cancer Res. 2008; 14: 1368 ‐ 1376. | en_US |
dc.identifier.citedreference | Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975‐2006 [based on November 2008 SEER data submission, posted to the SEER web site, 2009]. Bethesda, MD: National Cancer Institute; 2009. Available at: http://seer.cancer.gov/csr/1975_2006. [Accessed January 15, 2012.] | en_US |
dc.identifier.citedreference | Anderson WF, Luo S, Chatterjee N, et al. Human epidermal growth factor receptor‐2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) Program. Breast Cancer Res Treat. 2009; 113: 189 ‐ 196. | en_US |
dc.identifier.citedreference | Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996; 14: 2738 ‐ 2746. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.